Gordon Freeman
Gordon Freeman
Dana-Farber Cancer Institute, Harvard Medical SchoolUnknown affiliation
Verified email at
Cited by
Cited by
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman, AJ Long, Y Iwai, K Bourque, T Chernova, H Nishimura, ...
The Journal of experimental medicine 192 (7), 1027-1034, 2000
PD-1 and its ligands in tolerance and immunity
ME Keir, MJ Butte, GJ Freeman, AH Sharpe
Annu. Rev. Immunol. 26, 677-704, 2008
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber, EJ Wherry, D Masopust, B Zhu, JP Allison, AH Sharpe, ...
Nature 439 (7077), 682-687, 2006
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ...
New England Journal of Medicine 372 (4), 311-319, 2015
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Y Latchman, CR Wood, T Chernova, D Chaudhary, M Borde, I Chernova, ...
Nature immunology 2 (3), 261-268, 2001
The B7 family revisited
RJ Greenwald, GJ Freeman, AH Sharpe
Annu. Rev. Immunol. 23, 515-548, 2005
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
CL Day, DE Kaufmann, P Kiepiela, JA Brown, ES Moodley, S Reddy, ...
Nature 443 (7109), 350-354, 2006
CTLA-4 can function as a negative regulator of T cell activation
TL Walunas, DJ Lenschow, CY Bakker, PS Linsley, GJ Freeman, ...
Immunity 1 (5), 405-413, 1994
CD4+ CD25high regulatory cells in human peripheral blood
C Baecher-Allan, JA Brown, GJ Freeman, DA Hafler
The Journal of Immunology 167 (3), 1245-1253, 2001
The B7–CD28 superfamily
AH Sharpe, GJ Freeman
Nature Reviews Immunology 2 (2), 116-126, 2002
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
SD Blackburn, H Shin, WN Haining, T Zou, CJ Workman, A Polley, ...
Nature immunology 10 (1), 29-37, 2009
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
LM Francisco, VH Salinas, KE Brown, VK Vanguri, GJ Freeman, ...
Journal of Experimental Medicine 206 (13), 3015-3029, 2009
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
P Jiang, S Gu, D Pan, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, J Liu, ...
Nature medicine 24 (10), 1550-1558, 2018
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
MJ Butte, ME Keir, TB Phamduy, AH Sharpe, GJ Freeman
Immunity 27 (1), 111-122, 2007
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
MM Gubin, X Zhang, H Schuster, E Caron, JP Ward, T Noguchi, Y Ivanova, ...
Nature 515 (7528), 577-581, 2014
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney, CA Sabatos, JL Gaglia, A Ryu, H Waldner, T Chernova, ...
Nature 415 (6871), 536-541, 2002
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
AH Sharpe, EJ Wherry, R Ahmed, GJ Freeman
Nature immunology 8 (3), 239-245, 2007
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir, SC Liang, I Guleria, YE Latchman, A Qipo, LA Albacker, ...
The Journal of experimental medicine 203 (4), 883-895, 2006
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown, DM Dorfman, FR Ma, EL Sullivan, O Munoz, CR Wood, ...
The Journal of Immunology 170 (3), 1257-1266, 2003
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
SJ Im, M Hashimoto, MY Gerner, J Lee, HT Kissick, MC Burger, Q Shan, ...
Nature 537 (7620), 417-421, 2016
The system can't perform the operation now. Try again later.
Articles 1–20